RxDoctor Payments Data

Heather Popham, NP

Adult Health · Saint Louis, MONPI 1093086985

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 492 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 49 manufacturers reported payments, led by AbbVie at 25.4% of the total. Reporting peaked in 2021 at $3,047 and has fallen 64.1% since, to $1,094 in 2025. Among adult health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,150in general payments, 2019–2025

Across 492 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$645
  • Teva Pharmaceuticals USA, Inc.$600
  • SK Life Science, Inc.$587
  • Neurocrine Biosciences, Inc.$571
  • UCB, Inc.$439
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$10,150100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,150 in reported general payments places this provider in the 95th percentile of 555 adult health providers in Missouri.

See all adult health providers in Missouri

Medicare billing

Part B allowed, 2024
$42,201
Medicare patients
256
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine17$211,788
QuliptaAtogepant13$19,252
Levetiracetam36$1,116
Carbidopa-LevodopaCarbidopa/Levodopa17$1,037
Memantine Hcl37$1,005
Donepezil Hcl57$553
Divalproex Sodium36$517
Topiramate36$358
Lamotrigine13$263
Atorvastatin Calcium17$211
Gabapentin12$158
Quetiapine Fumarate15$131
Mirtazapine15$0

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$600$211,78817 claims
AbbVieQulipta$2,582$19,25213 claims
Upsher-smith Laboratories LLCTopiramate$19$35836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 555 adult health providers in Missouri.

Other adult health in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →